We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




First Implantable Cardioverter-Defibrillator System to Allow for Full-Body MRI Scans Launched

By MedImaging International staff writers
Posted on 01 May 2014
Print article
Image: The Evera MRI SureScan implantable cardioverter-defibrillator (ICD), shown with leads (Photo courtesy of Medtronic).
Image: The Evera MRI SureScan implantable cardioverter-defibrillator (ICD), shown with leads (Photo courtesy of Medtronic).
A new implantable cardioverter-defibrillator (ICD) system is the first to combine effective treatment performance, improved comfort, increased longevity, with full-body magnetic resonance imaging (MRI) access.

Medtronic (Minneapolis, MN, USA) announced the CE (Conformité Européenne) marking along with the European launch of the Evera MRI SureScan ICD system, the first and only ICD system approved for magnetic resonance imaging (MRI) scans positioned on any region of the body. The Medtronic Evera MRI ICD is not approved in the United States.

It is estimated that as many as 63% of ICD patients will need an MRI within 10 years of receiving a device. Until the availability of MR-Conditional ICD systems, patients with devices have been contraindicated from receiving MRI scans because of potential interactions between the MRI and device function.

“This means that in addition to having the highest standard in modern ICD treatment, patients implanted with an Evera MRI defibrillator will now have improved access to one of the most important diagnostic tools—the MRI,” said Marshall Stanton, MD, vice president and general manager of the tachycardia business at Medtronic. “An ICD that allows for full-body access to MRI will help patients get the diagnostic answers they need.”

Like its non-MR-Conditional predecessor, the Evera MRI features a contoured shape with thin, smooth edges that better fits inside the body, increasing patient comfort by reducing skin pressure by 30%.The Evera MRI maintains the same industry-leading battery longevity (up to 11 years) compared to previous devices. Furthermore, Evera MRI is paired with the Sprint Quattro Secure range of ICD leads, which has 10 years of established performance with active monitoring and is safe for use in an MRI setting.

Evera MRI includes SmartShock 2.0, a shock reduction algorithm that enables the device to better differentiate between dangerous and harmless heart rhythms. Whereas most of shocks delivered are necessary to treat potentially fatal arrhythmias, studies estimate that approximately 20% of patients with implantable defibrillators may experience inappropriate shocks in response to a benign arrhythmia or electrical noise sensed by the device. SmartShock technology helps to eliminate these inappropriate shocks, and delivers a 98% inappropriate shock-free rate at one year. Also included in the Evera MRI is OptiVol 2.0 fluid status monitoring and complete diagnostics, which helps to identify patients at risk of worsening heart failure and atrial fibrillation.

“Compared to other ICDs available, the Evera MRI system gives patients the most unrestricted access to MRI scans, and ultimately allows them to get the diagnostic answers they need,” said Dr. Stanton. “Patients suffering from debilitating heart rhythm disorders who need an ICD also are likely to need an MRI over the lifetime of their device and this technology allows them to do so.”

The Evera MRI system is the latest addition to a growing number of Medtronic devices that are designed for MRI access including the Medtronic SureScan pacing systems, neurostimulation systems for the management of chronic pain and the SynchroMed II programmable drug infusion system.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic provides a wide range of medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.

Related Links:

Medtronic


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Self-Driving Mobile C-arm
CIARTIC Move
New
Ultrasound System
Acclarix AX9
Compact C-Arm with FPD
Arcovis DRF-C R21

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.